Key Clinical Message: This case highlights the need for further research to explore a potential link between systemic sclerosis and fistula development, and the importance of raising awareness among clinicians about this possibility for timely appropriate management.
Abstract: The primary diagnosis in this case is systemic sclerosis (scleroderma) in a 47-year-old female patient with various clinical manifestations, including vesicovaginal and vesicorectal fistulas. The medical interventions and diagnostic workup involved an electrocardiogram, cardiac echocardiogram, pulmonary function tests, beta blockers, aspirin, inhaled corticosteroids, albuterol, endoscopy, biopsy, treatment for infection, fluconazole for candida esophagitis, endoscopic dilation for achalasia, anticholinergic therapy for mixed urinary incontinence, gabapentin for neuropathic symptoms, analgesia for knee pain, and psychiatric treatment with selective serotonin reuptake inhibitors. The outcomes described in the case report include the diagnosis of systemic sclerosis, the identification of vesicovaginal and vesicorectal fistulas, the patient's medical history and symptoms over the years, and various treatments and management strategies.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10883344 | PMC |
http://dx.doi.org/10.1002/ccr3.8550 | DOI Listing |
Front Immunol
January 2025
Department of Biomedical Sciences, University of Sassari, Sassari, Italy.
Introduction: The critical role played by vascular dysfunction and ineffective angiogenesis in the pathophysiology of systemic sclerosis (SSc) suggests that circulating biomarkers reflecting these alterations may be useful in the clinical evaluation of this patient group. We sought to address this issue by conducting a systematic review and meta-analysis of studies investigating a such candidate biomarker, endostatin, an endogenous glycoprotein exerting anti-angiogenic effects, in SSc patients and healthy controls.
Methods: A literature search was conducted in the electronic databases Web of Science, PubMed, and Scopus from inception to 27 May 2024.
Cureus
December 2024
Department of Rheumatology, Mayo Clinic, Jacksonville, USA.
The term Raynaud's phenomenon (RP) is used to describe complex symptoms related to vascular compromise, which are typically exacerbated by cold-induced vasoconstriction, emotional stress, or other sympathomimetic factors. In almost all patients with limited cutaneous systemic sclerosis (SSc), the first symptom is RP, often two to five years before any other symptom of scleroderma. The clinical course and severity of this disease are variable and highly fatal in some individuals, which has led to the development of strategies for timely diagnosis; hence, criteria for the very early diagnosis of systemic sclerosis have been established.
View Article and Find Full Text PDFJ Anaesthesiol Clin Pharmacol
November 2024
Department of Anaesthesiology, Pain Medicine and Critical Care, All India Institute of Medical Sciences, New Delhi, India.
Intern Med
January 2025
Department of Respiratory Medicine, University of Occupational and Environmental Health, Japan, Japan.
A 69-year-old man with systemic sclerosis and interstitial pneumonia presented with an abnormal shadow in the right upper lung lobe. A thoracoscopic needle biopsy was performed on the right upper lobe lesion, and Mycobacterium malmoense was identified by 16S rRNA and rpoB gene sequencing. Surgical treatment was performed to obtain a radical cure, and lung squamous cell carcinoma and M.
View Article and Find Full Text PDFJ Am Acad Dermatol
January 2025
Department of Dermatology, Yale School of Medicine, New Haven, Connecticut. Electronic address:
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!